Evotec AG (OTCMKTS:EVTCY)‘s stock had its “sell” rating restated by equities researchers at DZ Bank AG in a research report issued on Wednesday, November 8th.
Several other equities analysts have also commented on the company. Zacks Investment Research lowered Evotec from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Roth Capital reiterated a “buy” rating on shares of Evotec in a research note on Tuesday, July 25th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $68.00.
Shares of Evotec (OTCMKTS:EVTCY) opened at $29.66 on Wednesday. Evotec has a 12-month low of $12.30 and a 12-month high of $52.82. The stock has a market capitalization of $2,310.52, a price-to-earnings ratio of 61.76, a PEG ratio of 3.76 and a beta of 0.53.
Evotec Company Profile
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with our FREE daily email newsletter.